Telomerase based anticancer immunotherapy and vaccines approaches

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Telomerase is a reverse transcriptase essential for telomere maintenance, typically absent in somatic cells but active in stem cells, germ cells, and approximately 90% of cancers.
• Telomerase plays a critical role in the development and sustenance of cancer cells.
• As a Human Leukocyte Antigen (HLA) class-I antigen, telomerase can elicit a cell-mediated immune response via cytotoxic T-cells.

Purpose of the Study:

• To compile and review various Human Telomerase Reverse Transcriptase (hTERT)-based anticancer immunotherapy approaches and vaccines.
• To evaluate the performance and efficacy of these hTERT-derived vaccines in preclinical and clinical settings.

Main Methods:

• Literature review of studies and clinical trials investigating hTERT-based cancer vaccines.
• Analysis of the mechanisms by which hTERT vaccines stimulate immune responses, particularly cytotoxic T-cells.
• Assessment of vaccine-induced anticancer responses and toxicity profiles.

Main Results:

• hTERT-derived vaccines have demonstrated effective anticancer responses in numerous studies and clinical trials.
• These immunotherapies have shown efficacy without inducing toxicity in non-cancerous cells.
• The immune stimulation involves the induction of cytotoxic T-cells targeting telomerase-expressing cancer cells.

Conclusions:

• hTERT-based vaccines represent a viable strategy for cancer immunotherapy by harnessing the host's immune system.
• The targeted nature of these vaccines suggests a favorable safety profile, sparing healthy tissues.
• Further research and clinical application of hTERT vaccines hold significant potential for cancer treatment.